UBS Group’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-166,438
| Closed | -$2.62M | – | 10350 |
|
|
2024
Q1 | $2.62M | Buy |
166,438
+40,115
| +32% | +$617K | ﹤0.01% | 3668 |
|
|
2023
Q4 | $2.04M | Buy |
126,323
+68,064
| +117% | +$868K | ﹤0.01% | 3803 |
|
|
2023
Q3 | $741K | Sell |
58,259
-31,133
| -35% | -$430K | ﹤0.01% | 4351 |
|
|
2023
Q2 | $1.26M | Sell |
89,392
-6,004
| -6% | -$85.9K | ﹤0.01% | 4014 |
|
|
2023
Q1 | $1.47M | Sell |
95,396
-73,944
| -44% | -$1.23M | ﹤0.01% | 3743 |
|
|
2022
Q4 | $2.78M | Buy |
169,340
+128,397
| +314% | +$2.09M | ﹤0.01% | 3055 |
|
|
2022
Q3 | $758K | Sell |
40,943
-62,611
| -60% | -$983K | ﹤0.01% | 3983 |
|
|
2022
Q2 | $1.36M | Sell |
103,554
-308,424
| -75% | -$3.4M | ﹤0.01% | 3456 |
|
|
2022
Q1 | $3.82M | Sell |
411,978
-34,401
| -8% | -$293K | ﹤0.01% | 2803 |
|
|
2021
Q4 | $4.36M | Buy |
446,379
+415,783
| +1,359% | +$7.82M | ﹤0.01% | 2967 |
|
|
2021
Q3 | $1.04M | Buy |
30,596
+20,401
| +200% | +$651K | ﹤0.01% | 4170 |
|
|
2021
Q2 | $373K | Sell |
10,195
-30,866
| -75% | -$1.2M | ﹤0.01% | 4936 |
|
|
2021
Q1 | $1.84M | Buy |
41,061
+19,254
| +88% | +$896K | ﹤0.01% | 3640 |
|
|
2020
Q4 | $1.25M | Buy |
21,807
+2,323
| +12% | +$138K | ﹤0.01% | 3836 |
|
|
2020
Q3 | $1M | Buy |
19,484
+5,172
| +36% | +$253K | ﹤0.01% | 3641 |
|
|
2020
Q2 | $855K | Buy |
14,312
+11,367
| +386% | +$608K | ﹤0.01% | 3646 |
|
|
2020
Q1 | $121K | Sell |
2,945
-7,109
| -71% | -$395K | ﹤0.01% | 5122 |
|
|
2019
Q4 | $625K | Sell |
10,054
-46,875
| -82% | -$2.23M | ﹤0.01% | 4636 |
|
|
2019
Q3 | $1.93M | Buy |
56,929
+46,172
| +429% | +$1.37M | ﹤0.01% | 3321 |
|
|
2019
Q2 | $243K | Buy |
10,757
+2,927
| +37% | +$68.5K | ﹤0.01% | 4790 |
|
|
2019
Q1 | $182K | Sell |
7,830
-41,273
| -84% | -$1.08M | ﹤0.01% | 4659 |
|
|
2018
Q4 | $1.03M | Buy |
49,103
+43,892
| +842% | +$1.08M | ﹤0.01% | 3657 |
|
|
2018
Q3 | $202K | Sell |
5,211
-1,128
| -18% | -$41.7K | ﹤0.01% | 5053 |
|
|
2018
Q2 | $250K | Buy |
6,339
+1,659
| +35% | +$48.8K | ﹤0.01% | 4793 |
|
|
2018
Q1 | $94K | Buy |
4,680
+273
| +6% | +$6.92K | ﹤0.01% | 5262 |
|
|
2017
Q4 | $100K | Buy |
+4,407
| New | +$86.3K | ﹤0.01% | 5352 |
|
Other funds holding DCPH
UBS Group's DCPH Position: Q2 2024 in Review
UBS Group sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 166,438 shares — an estimated $2.62M sold.
UBS Group first reported a position in DCPH in Q4 2017 and held it in 26 quarters. The position peaked at $4.36M in Q4 2021. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- UBS Group reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- UBS Group sold 166,438 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $2.62M.
- UBS Group first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 26 quarters.
- UBS Group's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $4.36M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.